S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
NASDAQ:ACHL

Achilles Therapeutics Stock Forecast, Price & News

$3.76
-0.04 (-1.05%)
(As of 01/25/2022 02:57 PM ET)
Add
Compare
Today's Range
$3.67
▼
$3.81
50-Day Range
$3.80
▼
$5.60
52-Week Range
$3.55
▼
$18.95
Volume
206 shs
Average Volume
59,044 shs
Market Capitalization
$152.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ACHL News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Headlines

Achilles Therapeutics PLC: Achilles Therapeutics Provides Business Update and Outlook for 2022
January 13, 2022 |  finanznachrichten.de
Achilles to establish R&D facility in U.S. this year
January 13, 2022 |  seekingalpha.com
Achilles Therapeutics Provides Business Update and Outlook for 2022
January 13, 2022 |  finance.yahoo.com
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
December 28, 2021 |  finance.yahoo.com
Achilles Therapeutics Plc - ADR Shares Close the Day 10.1% Higher - Daily Wrap
December 24, 2021 |  nasdaq.com
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 |  ca.finance.yahoo.com
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 |  finance.yahoo.com
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
December 20, 2021 |  finance.yahoo.com
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
December 20, 2021 |  finance.yahoo.com
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
December 9, 2021 |  finance.yahoo.com
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
November 12, 2021 |  finance.yahoo.com
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
November 10, 2021 |  finance.yahoo.com
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACHL
Previous Symbol
CUSIP
N/A
CIK
1830749
Web
www.achillestx.com
Phone
44-20-8154-4600
Fax
N/A
Employees
153
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-33.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-22.38%
Return on Assets
-20.13%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
19.41
Quick Ratio
19.41

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
40,603,000
Free Float
N/A
Market Cap
$152.67 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/25/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.95 out of 5 stars

Medical Sector

685th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

109th out of 206 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Achilles Therapeutics (NASDAQ:ACHL) Frequently Asked Questions

Is Achilles Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Achilles Therapeutics stock.
View analyst ratings for Achilles Therapeutics or view top-rated stocks.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) announced its earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.14.
View Achilles Therapeutics' earnings history.

What price target have analysts set for ACHL?

5 Wall Street analysts have issued 12-month target prices for Achilles Therapeutics' shares. Their forecasts range from $11.00 to $27.00. On average, they anticipate Achilles Therapeutics' stock price to reach $20.80 in the next twelve months. This suggests a possible upside of 453.2% from the stock's current price.
View analysts' price targets for Achilles Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Achilles Therapeutics' key executives?

Achilles Therapeutics' management team includes the following people:
  • Dr. Iraj Ali, CEO & Director (Age 45)
  • Dr. Karl Peggs M.D., Founder & Chief Medical Officer (Age 54)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Founder (Age 58)
  • Dr. Charles Swanton, Founder (Age 49)
  • Dr. Sergio A. Quezada Ph.D., Founder & Chief Scientific Officer (Age 46)
  • Mr. Robert Coutts, Chief Financial Officer (Age 37)
  • Mr. Lee M. Stern, VP of Investor Relations & External Communications
  • Mr. Daniel Hood, Chief Legal Officer
  • Julia Wilson, Head of Communications
  • Mr. Tariq Ahmed, VP of People

When did Achilles Therapeutics IPO?

(ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

What is Achilles Therapeutics' stock symbol?

Achilles Therapeutics trades on the NASDAQ under the ticker symbol "ACHL."

How do I buy shares of Achilles Therapeutics?

Shares of ACHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achilles Therapeutics' stock price today?

One share of ACHL stock can currently be purchased for approximately $3.76.

How much money does Achilles Therapeutics make?

Achilles Therapeutics has a market capitalization of $152.67 million.

How many employees does Achilles Therapeutics have?

Achilles Therapeutics employs 153 workers across the globe.

What is Achilles Therapeutics' official website?

The official website for Achilles Therapeutics is www.achillestx.com.

Where are Achilles Therapeutics' headquarters?

Achilles Therapeutics is headquartered at 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW.

How can I contact Achilles Therapeutics?

Achilles Therapeutics' mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The company can be reached via phone at 44-20-8154-4600 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.